The Rapid Growth of the Transthyretin Amyloid Cardiomyopathy Treatment Market Driven by Rising Prevalence of Amyloidosi

Transthyretin Amyloid Cardiomyopathy Treatment Market

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, fatal disease characterized by the buildup of abnormal deposits of amyloid protein in the heart. The deposits interfere with the normal functioning of the heart and can lead to heart failure if left untreated. Current treatment options for ATTR-CM include drugs that slow progression of amyloid deposits, gene silencing therapies, and heart or liver transplants.

The global transthyretin amyloid cardiomyopathy treatment market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031. Rising prevalence of amyloidosis, growing geriatric population, and robust pipeline of drugs are fueling market growth.

Key Takeaways

Key players operating in the transthyretin amyloid cardiomyopathy treatment market are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC (HydraFacial), among others. Rising prevalence of amyloidosis and ATTR-CM is driving increased demand for treatment options. The rate of amyloidosis and ATTR-CM is growing as people are living longer, and new treatment options are extending life expectancies. Technological advancements are expanding treatment options for ATTR-CM. New gene therapies aim to halt or reverse disease progression by silencing the defective gene or replacing it.

Market Trends

Gene silencing therapies are emerging as a promising new treatment strategy. These therapies use RNA interference to block production of the misfolded transthyretin protein that causes amyloid deposits. Patisiran and inotersen have shown success in clinical trials at reducing amyloid deposits and improving cardiac function and survival. Heart transplants remain the only cure but are in short supply. Non-heart organ transplants and drug treatments that stabilize the disease are expanding options.

Impact of COVID-19 on Transthyretin Amyloid Cardiomyopathy Treatment Market:

The COVID-19 pandemic has severely impacted the growth of the Transthyretin Amyloid Cardiomyopathy Treatment Market Size. Lockdowns imposed worldwide forced healthcare facilities to postpone non-critical procedures and elective surgeries to focus on treating COVID-19 patients. This led to disruptions in the supply chain and manufacturing of drugs and therapies used for Transthyretin Amyloid Cardiomyopathy treatment. Research and development activities were also temporarily halted or delayed. Patients suffering from Transthyretin Amyloid Cardiomyopathy became hesitant to visit hospitals for treatment due to fear of contracting the virus. Post COVID however, the market is expected to recover steadily as production resumes and supply chains stabilize to meet the growing demand. Healthcare systems have also become better equipped to handle non-COVID patients while taking necessary precautions. Pharmaceutical companies are accelerating their efforts to develop more targeted drugs and effective management strategies to capture the treatment needs of patients.

Concentration of Transthyretin Amyloid Cardiomyopathy Treatment Market by Geographical Regions:

In terms of value, the Europe region holds the largest share of the global Transthyretin Amyloid Cardiomyopathy Treatment market currently. This is attributed to factors such as rising incidence of the disease, availability of advanced treatment options, growing awareness, and favorable healthcare policies supporting drug development in countries like Germany, UK, France and Italy. The United States holds the second largest market share due to high healthcare expenditure, presence of major market players and focus on innovative research.

Fastest Growing Region in the Transthyretin Amyloid Cardiomyopathy Treatment Market:

The Asia Pacific region is poised to be the fastest growing market for Transthyretin Amyloid Cardiomyopathy Treatment over the forecast period. This accelerated growth can be credited to increasing healthcare investments, expanding private insurance coverage, growing medical tourism industry, rising affordability, and burgeoning patient population in emerging countries like China and India. In addition, supportive initiatives by governments to boost local manufacturing and presence of international brands are aiding the regional market growth.

Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment Market